Monoclonal antibody-based cancer immunotherapy
10.16438/j.0513-4870.2020-0135
- VernacularTitle:基于单克隆抗体的肿瘤免疫治疗
- Author:
Rong-guang SHAO
1
Author Information
1. NHC Key Laboratory of Antibiotic Bioengineering, Institute of Medicinal Biotechnology, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100050, China
- Publication Type:Research Article
- Keywords:
cancer immunotherapy;
monoclonal antibody;
bispecific antibody;
CAR-T cell;
combination therapy
- From:
Acta Pharmaceutica Sinica
2020;55(6):1110-1118
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, cancer immunotherapy has become an important field of basic and applied researches of cancer immunology. Cancer immunotherapy mainly includes cancer vaccine, oncolytic virus therapy, chimeric antigen receptor T cells (CAR-T cells), immune checkpoint blocks, monoclonal antibodies, and other strategies. Among them, monoclonal antibody-based cancer immunotherapy has the fastest development. In the past 20 years, monoclonal antibody has become one of the drugs with remarkable curative effect and novel type for human malignant tumors, especially the monoclonal antibody targeting immune checkpoints, play an important role in immunotherapy. In this review, we will summarize the current situation of monoclonal antibody-based cancer immunotherapy, potential immune modulatory mechanism, antibody targeting molecules and its immunotherapeutic agents, and explore the trend of monoclonal antibody-based agents in cancer immunotherapy.
